Day: February 21, 2023

February 21, 2023

• 1.81 billion lives improved by Philips’ health technology products, services and solutions
• Philips became the first health technology company to obtain approval by the Science Based Targets initiative (SBTi) for its entire value-chain CO₂ emissions reduction targets, including Scope 1-3
• Continued recognition for sustainability leadership – received CDP’s ‘A List’ rating for 10th year in a row
• Actively engaging with suppliers and customers to help reduce emissions across the end-to-end healthcare value chain
• With 77% renewable energy usage, Philips is well ahead of its 2025 goal
  

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has made strong progress towards realizing its key Environmental, Social, and Governance (ESG) ambitions. In 2022, Philips reached 1.81 billion people with its products and services, while further reducing operational emissions, and indirect (scope 3) emissions across the end-to-end healthcare value chain, together with its suppliers.

“We continue to move closer to our aim of improving 2 billion lives per year by 2025, while stepping up our sustainability efforts in our operations and value chain,” said Marnix van Ginneken, Chief ESG & Legal Officer at Royal Philips. “The growing momentum across the healthcare industry and among customers to reduce our collective environmental footprint encourages us on a daily basis as we continue to strive to reduce emissions across the end-to-end healthcare value chain and drive the shift to a circular economy.”

Increasing social impact
Illustrating the company’s increasing social impact, Philips’ health technology products, services and solutions improved 1.81 billion lives (1.67 billion in 2021), of which 202 million in underserved communities. This takes Philips closer to its goal of improving 2 billion lives per year by 2025, with 300 million in underserved communities. In 2022, improved access to care in underserved communities was driven by shared-value partnerships, the development of innovative digital solutions, and the roll-out of new business and financing models that are both sustainable and scalable.

Other key developments within the social dimension include a 30% representation of women in senior leadership roles, increased focus on employee health and well-being (both physical and mental health), and continued emphasis on ensuring a safe and healthy workplace.

Creating sustainable innovations
In 2022, the contribution from circular revenues increased to 18% of sales (2021: 16%). In 2022, Philips saw 10% more returns of large medical equipment compared to 2021 and closed the loop on more than 3,500 systems. Additionally, consumers started to make use of the newly introduced options to rent a Philips Avent breast pump or IPL Lumea hair removal device.

EcoDesigned products and solutions increased their revenue contribution to 71.7% (2021: 70.5%), supported by grooming and beauty products that contain over 25% recycled plastics and Oral Healthcare introducing its first brush heads containing 75% bio-based materials. Demand for sustainable healthcare systems is supported by the MR 5300 with its industry-leading BlueSeal magnet, helping radiology departments massively reduce the need for scarce helium gas.

Reducing operational emissions and waste
In addition to remaining carbon-neutral in its operations (since 2020), Philips achieved 77% (2021: 74%) renewable energy usage, exceeding the 75% goal for 2025. It also reduced transport- and distribution-related CO₂ emissions by 22% through a stricter air-freight policy and optimized warehouse locations.

Philips improved the circularity of its waste stream to 91% (2021: 87%), increasingly recycling, re-using or reducing waste. An example is the replacement of single use plastic in supplier packaging with boxes that can be used repeatedly. As a result, less than 0.1% of the remaining operational waste was land-filled, in line with our zero-waste to landfill ambition.

Philips is also proud that CDP, a global NGO that assesses the CO₂ emissions performance and management of reporting companies, ranked Philips on the CDP Climate Change ’A’ List for the 10^th time in a row, thanks to the company’s continued climate performance and transparency.

Advancing towards low-carbon operations and value chain
In 2022, Philips became the first health technology company with approval from the Science Based Targets initiative (SBTi) for its entire value-chain CO₂ emissions reduction targets, including Scope 1-3. In addition, 41% of suppliers (based on spend) have now committed to science-based targets (2021: 28%) – Philips’ goal is 50% by 2025.

Progressing in governance
Philips’ commitment to responsible and transparent governance is illustrated by the publication of the Philips Human Rights Report 2022, in which Philips updated stakeholders on its progress in addressing key human rights over the past year, along with plans for continuous improvement.

Philips continues to take an active role – in collaboration with global institutions such as the International Financial Reporting Standards (IFRS) Foundation, the World Economic Forum (WEF) and the European Union – to help drive the evolution towards a standard global ESG reporting framework.

For a full overview of Philips’ Environmental, Social, and Governance achievements, read chapter 5 of the Philips Annual Report 2022, which was published earlier today.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips MR5300 in use
• Refurbishment process

GlobeNewswire Distribution ID 1000783790

February 21, 2023

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2022. Philips’ Annual Report 2022 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 9, 2023. The convocation notice and the agenda, including explanatory notes, for the AGM 2023 will be published in due course.

2022 was a very disappointing year for Philips and its stakeholders, and as recently announced, the company is taking firm action to strengthen patient safety and quality, improve its execution and step up performance with urgency in 2023.

The 2022 Remuneration Report, as included in the Annual Report 2022, will also be on the agenda of the AGM 2023. In his letter to Philips’ stakeholders, the Chairman of the Remuneration Committee explains that the Committee has been very mindful of the shareholder sentiment and the advisory vote regarding the 2021 Remuneration Report cast at the AGM 2022. The Remuneration Committee reports on how it reached out to the company’s shareholders immediately after the AGM 2022, and how the feedback received from shareholders in the second half of 2022 has been addressed.

The Remuneration Report furthermore explains how the remuneration in respect of the year 2022 has been impacted by Philips’ performance in 2022. In this context, and to further align with the company performance, as well as the sentiment and negative experience of the company’s shareholders and other stakeholders, the Supervisory Board and current Board of Management have jointly concluded that it was appropriate to waive any 2022 Annual Incentive (AI) pay-out and any vesting of the 2020 Long-term Incentive (LTI) grant of the members of the Board of Management.

Philips filed the Annual Report 2022 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to file the report on Form 20-F with the U.S. Securities and Exchange Commission later today (www.sec.gov).

The Annual Report 2022 (in ESEF and on Form 20-F) is available to shareholders and other interested parties at www.results.philips.com. A printed copy can be obtained free of charge upon written request to the following email address: annual.report@philips.com.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

GlobeNewswire Distribution ID 1000783787

SHANGHAI, China, Feb. 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that the pre-specified interim analysis has been completed for a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“TORCHLIGHT Study”, NCT04085276) examining the company’s product toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV or recurrent/metastatic triple-negative breast cancer. The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint met the pre-defined efficacy boundary. Junshi Biosciences will communicate with the regulatory authorities regarding matters related to the supplemental new drug application in the near future.

According to GLOBOCAN 2020, breast cancer had the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, triple-negative breast cancer (“TNBC”) accounted for approximately 15% to 20% of them. TNBC is a more aggressive type of tumor with a higher risk of recurrence and poor prognosis. Advanced TNBC is insensitive to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.

In recent years, oncology immunotherapy drugs represented by PD-(L)1 inhibitors have achieved a series of breakthroughs in treating various types of tumors. However, to this day, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combined chemotherapy have poor efficacy, with a median survival time of about nine to 12 months and a 5-year survival rate of less than 30%.

The TORCHLIGHT study is the first Phase III registration study in China to achieve a positive outcome in an advanced triple-negative breast cancer immunotherapy. This randomized, double-blind, placebo-controlled, multi-center Phase III clinical study was designed to compare the safety and efficacy of toripalimab combined with paclitaxel for injection (albumin-bound) and placebo combined with paclitaxel for injection (albumin-bound) in patients with an initial diagnosis of stage IV breast cancer or recurrent/metastatic triple-negative breast cancer.

The interim analysis of this study demonstrated that, compared with paclitaxel for injection (albumin-bound), toripalimab in combination with paclitaxel for injection (albumin-bound) in patients with initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer can significantly prolong the progression-free survival (PFS) of PD-L1 positive patients. Meanwhile, the overall survival (OS), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients regardless of PD-1 status. The safety data of toripalimab is consistent with known risks, and no new safety signals were identified.

“The TNBC subtype of breast cancer is the most aggressive and has the worst prognosis,” said Professor Zefei JIANG from the Department of Oncology at the Chinese People’s Liberation Army General Hospital, the Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Principal Investigator of the TORCHLIGHT study. “Advanced TNBC patients have limited survival rates and lack effective treatment methods. Aiming to improve patient survival, a group of Chinese researchers successfully conducted the first phase III study on immune-oncology for advanced TNBC patients, even amidst the COVID-19 pandemic, and achieved breakthrough results. These results demonstrate that the combined use of the monoclonal antibody, toripalimab, with traditional chemotherapy significantly prolonged the PFS of patients, and this has the potential to become a new standard treatment for patients with an initial diagnosis of stage IV TNBC as well as those with recurrent/metastatic TNBC, offering patients new hope!”

“I’m extremely pleased that TORCHLIGHT research has been successful, and its success is a result of the dedicated efforts of patients, researchers, and development teams,” said Dr. Jianjun ZOU, the President of Global Research and Development at Junshi Biosciences. “We will work closely with regulatory authorities to ensure that relevant indications are approved as soon as possible. We hope that toripalimab will provide better treatment options for patients and address unmet medical needs.”

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than thirty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

1. unresectable or metastatic melanoma after failure of standard systemic therapy;
2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

In terms of international layout, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). In December 2022 and February 2023, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma, respectively.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8753126

LONDON, Feb. 20, 2023 (GLOBE NEWSWIRE) — Following the successful completion of seed and private rounds and 9 figures trading volumes on their copy trading platform, Mizar (MZR Inc) is excited to announce its upcoming Token Generation Event, on 9th March 2023.

Since the open Beta release, Mizar has been striving to bring a token to make crypto trading easier for everyone. Having completed all major milestones in their project roadmap, the team is now moving towards the next step – rolling out an unprecedented, subscription-free social trading platform.

Cino Gerard, COO, is confident about the team’s capabilities and sees a bright future.

“What I love about Mizar is the community. We have been diligently building this product together with many of our users who helped us craft the roadmap, refine the product, and deliver something that people use, every day. That’s what brought us more than ten thousand users a few months after releasing the open Beta.”

Francesco Ciuci, CEO, is excited to announce the upcoming event.

“Our goal is to make Mizar the most powerful social trading platform, providing an amazing set of tools for traders to manage their assets and enabling them to share their trading strategies with the Mizar community. The TGE is an important milestone for all of us and our users are waiting for this for a couple of months now!”

Talking about the MZR Token, he added:

“The MZR Token provides various benefits to both users and investors, such as fees reduction up to 95% and strong token economics, enabling users to generate passive income and contribute to the platform’s progress and expansion.”

Mizar is approaching the conclusion of its CeFi Roadmap Phase, which focuses on developing all trading services on Centralized Exchanges like Binance. After completion, Mizar will enter its DeFi Phase, expanding its services to Decentralized Exchanges, and adding analytics and Machine Learning to support traders to make well-informed decisions.

About Mizar

With over 10,000 users trading millions in volume daily, Mizar is the choice for those who demand the best when trading crypto. Say goodbye to FOMO and missed opportunities, and embrace hands-free trading on your favorite CEX and DEX with advanced bots and smart tools. Share your bots with others on the best social trading platform in the crypto world and earn a passive income.

Photo: https://www.globenewswire.com/NewsRoom/AttachmentNg/2896a32c-4e7f-415f-b7f0-cdc0c5b7d4ff

Media Contact:
hello@mizar.com

GlobeNewswire Distribution ID 8752989